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Abstract: Unravelling the complex molecular pathways responsible for motor neuron degeneration
in amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) remains a persistent
challenge. Interest is growing in the potential molecular similarities between these two diseases,
with the hope of better understanding disease pathology for the guidance of therapeutic development.
The aim of this study was to conduct a comparative analysis of published proteomic studies of ALS
and SMA, seeking commonly dysregulated molecules to be prioritized as future therapeutic targets.
Fifteen proteins were found to be differentially expressed in two or more proteomic studies of both
ALS and SMA, and bioinformatics analysis identified over-representation of proteins known to
associate in vesicles and molecular pathways, including metabolism of proteins and vesicle-mediated
transport—both of which converge on endoplasmic reticulum (ER)-Golgi trafficking processes.
Calreticulin, a calcium-binding chaperone found in the ER, was associated with both pathways
and we independently confirm that its expression was decreased in spinal cords from SMA and
increased in spinal cords from ALS mice. Together, these findings offer significant insights into
potential common targets that may help to guide the development of new therapies for both diseases.
Keywords: spinal muscular atrophy (SMA); amyotrophic lateral sclerosis (ALS); proteomics;
bioinformatics; endoplasmic reticulum-Golgi trafficking; ER-Golgi trafficking; calreticulin (CALR);
endoplasmic reticulum; calcium
1. Introduction
The term “motor neuron disease” incorporates several conditions, including the most
common adult form, amyotrophic lateral sclerosis (ALS), and the predominantly childhood form,
spinal muscular atrophy (SMA); both of which represent a devastating cause of disability, morbidity,
and mortality. ALS is clinically characterized by muscular atrophy due to loss of motor neurons in
the anterior horn of the spinal cord (“lower motor neurons”) and spasticity due to loss of cortical
neurons (“upper motor neurons”) [1]. While approximately 90% of ALS cases occur sporadically
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(sALS), the remaining 10% of cases are attributable to a familial form of ALS (fALS) that typically follow
an autosomal dominant inheritance pattern [2]. Genetic mutations have been identified accounting
for half of the fALS cases, including mutations in the superoxide dismutase 1 (SOD1) gene, the TAR
DNA Binding protein-43 (TDP-43) gene, the fused-in-sarcoma (FUS) gene, and a hexonucleotide repeat
within the C9orf72 gene [3]. SMA is also primarily characterized by loss of lower motor neurons and
subsequent muscular atrophy, but without upper motor neuron involvement [4]. For >95% of SMA
patients, the disease is caused by a loss-of-function defect in the SMN1 gene, resulting in reduced
levels of the ubiquitously-expressed survival of motor neuron (SMN) protein [5].
Unravelling the genetic basis of SMA and a proportion of ALS cases has been influential in guiding
the direction of research, allowing for the development of animal models to further expand the study
of motor neuron diseases. There is no cure for either disease, though some progress has been made in
recent years towards the development of therapies that may extend survival or alleviate symptoms
(reviewed for SMA [6], and for ALS [7]). Despite numerous clinical trials for ALS therapies, the only
clinically approved treatments are riluzole, which may prolong survival by a modest 2–3 months,
and edaravone, which was recently approved by the FDA to slow disease progression [8]. In 2017,
nusinersen received clinical approval as the first antisense oligonucleotide gene therapy for SMA
treatment. Clinical trial data suggests that treatment with nusinersen significantly improved disease
symptoms for approximately 50% in patients with the most severe form of SMA (SMA Type I) [9,10],
with a more modest effect in older patients [9–11]. There is a keen interest, therefore, to find alternative
approaches to SMA and ALS therapy. For SMA, the need to tailor these treatments to the stage of
development, the severity of disease, and to the effects of aging is widely recognized, but development
has been hindered by lack of understanding of the mechanisms involved in disease pathogenesis
and progression [6]. The disease mechanisms of ALS are likely to be even more complex, especially
considering that approximately 90% of cases still have an unexplained etiology.
Despite variation in the genetic basis of fALS and sALS, there is little difference recognized in their
clinical presentation (aside from younger age at presentation in fALS) or any phenotypic pattern related
to different genes [1,12]. This would suggest that the disease mechanisms of ALS likely converge on
common molecular pathways, regardless of the etiology, that ultimately result in similar phenotypes.
This then raises the question of whether there are core regulatory pathways involved in motor neuron
disease pathology, in general, that may prove useful for guiding research into therapeutic development.
Not unsurprisingly, therefore, the potential molecular similarities between ALS and SMA are receiving
attention. Several recent reviews have discussed the current knowledge of pathways upon which
both diseases appear to converge, including RNA processing pathways [13,14] and the TRAF6-nuclear
factor kappa B (NF-κB) pathway [15]. Whilst these pathways certainly warrant further investigation,
the precise molecular overlap between ALS and SMA is yet to be determined.
Quantitative proteomics technology is well equipped to examine the complex molecular biology of
both ALS and SMA and has been employed by research groups to study a range of cells and tissues from
patients and animal models. Generation of these big datasets, however, has typically been followed
by selection of several candidates for further examination, while most of the detected molecular
changes have received little or no further attention. As a result, it is quite likely that important
molecular changes have been overlooked, particularly at the level of molecular networks and pathways.
Indeed, we previously interrogated published SMA proteomic datasets, and identified several proteins
that were consistently dysregulated across multiple studies that had not previously been studied
in association with SMA [16]. Importantly, this approach also highlighted conserved molecular
responses to reduced SMN already proven to be directly relevant to SMA disease pathogenesis [16].
This provides confidence that multi-study comparison of proteomics data is a valid approach to finding
disease-relevant targets for therapy design.
Here, we have applied the same approach to interrogate a range of ALS proteomic datasets
to gain new insights into mechanisms of disease pathogenesis. By systematically comparing the
resulting pooled dataset with the previously published dataset of conserved molecular alterations
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in SMA [16], we highlight the core molecular overlap between both diseases and use bioinformatics
tools to understand the pathways upon which they converge. In addition, we report that calreticulin, a
calcium-binding chaperone involved in the regulation of nascent protein folding [17], is associated
with several perturbed pathways and we confirm that its expression levels are altered in spinal cords
from both SMA and ALS mice.
2. Materials and Methods
2.1. Identification of ALS Proteomic Studies
PubMed searches were performed to identify eligible studies for comparison, using combinations
of the terms: “amyotrophic lateral sclerosis”, “Lou Gehrig’s disease” or “motor neuron disease” AND
“proteomics” or “mass spectrometry”. The search was conducted to include studies published up
to 1 July 2018, and published studies were considered eligible for inclusion if they had applied an
unbiased proteomics approach to identify disease-specific protein patterns in ALS. Studies that utilized
a targeted approach (i.e., seeking specific proteins) for initial protein identification were excluded.
Initially 40 studies were eligible for review, but seven studies were further excluded from the list due
to inaccessible or incomplete data (i.e., lack of access to complete article, only some results published
or accessible), leaving 33 studies in total. Of these, 12 studies examined proteome changes in biofluids
from ALS patients and 21 studies examined proteome changes in cells and tissues from ALS models
(Table S1).
2.2. Comparison of ALS Proteomic Studies
The studies eligible for review applied a variety of strategies in data analysis and processing,
and so it was therefore necessary to establish a method of data selection for the comparison.
First, only proteins changed in expression in ALS compared to healthy controls were considered
for analysis. Proteins that were differentially expressed between ALS and diseased controls (e.g.,
Alzheimer’s disease (AD)), protein changes identified between different groups of ALS patients,
and/or protein changes identified between different regions of the same tissue were disregarded.
Results from studies that used multiple groups in proteomic comparison were filtered so that only
proteins that showed differential expression between ALS and healthy controls were included in the
comparison. Proteomic datasets were first extracted into a Microsoft Excel spreadsheet. To facilitate an
achievable and accurate method for comparison between the studies the protein identifiers from each
study were then converted to official gene symbols using the Database for Annotation, Visualization
and Integrated Discovery (DAVID 6.8) [18,19]. If protein identifiers were not provided, or if DAVID
could not recognize the accession number, identifiers were assigned manually by searching for protein
names using the National Center for Biotechnology Information (NCBI) with the appropriate species
filter to identify the corresponding accession number. Rarely, proteins had been removed from the
NCBI database and so were not included in the final analysis. Most studies presented changes in the
protein expression as a fold change (FC) difference between ALS and controls, after having applied a
cut-off value to identify proteins that were differentially expressed in ALS. In cases where the cut-off
value for fold change was not applied, only proteins that showed at least 20% change in the expression
were included in the comparison. (This value was chosen because it has been commonly used in other
published proteomic studies to identify differentially expressed proteins e.g., [20–22]). The final lists of
gene names were then compared using Microsoft Excel’s ‘pivot table’ function to identify proteins that
appeared in multiple studies.
2.3. Bioinformatics Analysis
The DAVID [18,19] platform was used to investigate the likely function of proteins that showed
consistent change in expression across ALS studies. Gene ontology (GO) analysis was conducted to
include terms that had at least three annotated proteins and a p-value ≤ 0.05. Redundant terms (i.e.,
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those that were describing the same function and had identical matches, e.g., response to oxidative
stress and removal of superoxide radicals) were combined into one term. Search Tool for the Retrieval
of Interacting Genes/Proteins (STRING) 10 [23] was used to identify statistically significant interactions
between proteins that showed consistent change in expression in ALS. Association network analysis
was performed with high confidence (0.700) interaction score to exclude false positive results.
2.4. Comparison of SMA and ALS Proteome Changes
Differentially expressed proteins identified in the present ALS comparison (Tables S2–S5) were
compared with the differentially expressed proteins identified in our previous multi-study comparison
of SMA proteomic datasets [16] to investigate common molecular patterns between the two diseases.
Proteins with dysregulated expression in both SMA and ALS datasets were subjected to bioinformatics
analysis using DAVID [18,19] and STRING 10 [23] as described above. The Reactome curated
database [24] was then used to explore functional relationships between proteins by analyzing which
pathways they map to and any known “reactions” within those pathways (i.e., individual steps in
pathways that are known to change the state of a biological molecule). Reactome employs a binomial
test to calculate the probability for each result, and p-values are corrected for the multiple testing using
the Benjamini–Hochberg procedure.
2.5. Animal Models
For western blotting and immunohistochemistry experiments, the Taiwanese mouse model of
severe SMA (Smn−/−; SMN2tg/o) on a congenic FVB background [25] and age-matched phenotypically
normal controls (Smn+/−; SMN2tg/o) were obtained from breeding stock at the University of Edinburgh
(Home Office license number PPL60/4569) and the ALS mouse model (SOD1G93A) [26] and 20-week-old
age/gender-matched wild-type (WT) littermates were obtained from the University of Oxford (Home
Office number PDFEDC6F0). The breeding strategy and genotyping using standard PCR protocols,
were employed as previously described [27]. For quantitative PCR (qPCR) analysis, spinal cords were
harvested from Taiwanese SMA (Smn−/−; SMN2tg/o) and control mice (Smn+/−; SMN2tg/o) as well as
from 20-week-old SOD1G93A males and age/gender matched WT littermates housed at the University
of Oxford (Home Office number PDFEDC6F0). All animal work was carried under the appropriate
Project and Personal Licenses from the UK Home Office and following local ethical review.
2.6. Western Blotting
Spinal cords from postnatal day 8 (P8) SMA mice (n = 5) and healthy littermate mice (n = 5),
and 20 week-old ALS mice (n = 5) and WT littermate mice (n = 4) were left on ice for 15 min in 2×
modified RIPA buffer (2% NP-40, 0.5% Deoxycholic acid, 2 mM EDTA, 300 mM NaCl and 100 mM
Tris-HCl (pH 7.4)), homogenised using pellet pestles and sonicated briefly 2–3 times every 10 min.
Samples were centrifugated at 13,000 RPM (MSE, Heathfield, UK; MSB010.CX2.5 Micro Centaur) for 5
min at 4 ◦C to pellet any insoluble material. Protein extracts were subjected to SDS-PAGE and western
blotting. Briefly, samples were boiled in 2× SDS sample buffer (4% SDS, 10% 2-mercaptoethanol,
20% glycerol, 0.125 M Tris-HCl (pH 6.8) and bromophenol blue) for 3 min at 95 ◦C and subjected to
SDS-PAGE (Biorad, Hercules, CA, USA) using 4–12% Bis-Tris polyacrylamide gels (Life Technologies,
Warrington, UK). A slice of the gel was excised and stained with Coomassie blue as an internal loading
control for total protein. The proteins in the remaining part of the gel were transferred to nitrocellulose
membrane by western blotting overnight. After blocking with 4% powdered milk in PBS for one
hour, the membranes were incubated with rabbit anti-calreticulin antibody (Bio-techne, Abingdon,
UK; NB600-103SS; 1:500) in dilution buffer (1% fetal bovine serum, 1% horse serum, 0.1% BSA in PBS
with 0.05% Triton X-100) at room temperature for one hour, followed by incubation with HRP-labelled
goat anti-rabbit Ig (Agilent, Stockport, UK; P0488) in dilution buffer at 0.25 ng/mL. Between each step
membranes were washed three times with PBS for five minutes. Membranes were incubated with
West Femto (Thermo Fisher, Paisley, UK) and visualized using a Gel Image Documentation system
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(Bio-Rad, Deeside, UK). Densitometry measurements of antibody reactive bands were obtained using
Fiji software (version 1.51) [28] and were normalized to densitometry measurements of the Coomassie
stained gel. For densitometry measurements only, contrast and brightness were adjusted uniformly
across the gel and blot to decrease the background and enhance signal detection. After first testing
whether the data was normally distributed using a Shapiro–Wilk normality test, independent a two-tail
t-test was used to determine whether there was a statistically significant difference between WT and
ALS mice, and a Mann–Whitney U test was used to test for significant difference between healthy
controls and SMA mice. All statistical analyses were performed in SPSS version 24 (IBM, New York,
NY, USA).
2.7. Immunohistochemistry
For immunohistochemistry, spinal cords from P8 SMA mice and healthy littermates,
and 20 week-old ALS mice and WT littermates were fixed in 4% PFA for 24 h, followed by
cryopreservation in 30% sucrose for another 24 h. Lumbar spinal cord sections (25 µm) were
permeabilised with 0.3% Triton X-100 in PBS for ten minutes and blocked for one hour in 4% BSA/PBS
with 0.1% Triton X-100 or in 10% goat serum/PBS. After incubation with rabbit anti-calreticulin
antibody (Abcam, Cambridge, UK; EPR3924; 1:250) in blocking buffer (4% BSA/PBS with 0.1% Triton
X-100 or 4% BSA/PBS with 0.1% Triton X-100 and 1% goat serum) overnight at 4 ◦C, sections were
incubated with goat anti-rabbit IgG Alexa Fluor 546 (Life Technologies, Warrington, UK; A11010) or
goat anti-rabbit IgG Alexa Fluor 488 (Life Technologies, Warrington, UK; A11034) for one hour at
5 µg/mL, followed by 4′,6-diamidino-2-phenylindole (DAPI) staining (Sigma Aldrich, Gillingham,
UK; 0.4 µg/mL) for 10 min and mounted using Hydromount (Fisher Scientific, Loughborough, UK).
Between each step sections were washed with PBS three times for ten minutes. Images were obtained
using Leica SP5 confocal microscope with 63× oil immersion objective. Densitometry measurements of
calreticulin staining in motor neurons of the anterior horn were performed using Fiji software (version
1.51) [28]. First, images were calibrated using a calibrated step tablet. A rectangular selection that
filled most of the step without overlapping another one was created to measure mean grey value of
the first step. The same rectangular selection was then used to measure the mean grey value of all
the consecutive steps in the tablet. Measured values were plotted against standard measurements
of optical density (OD) to create a calibration curve. Prior to analysis, the mean OD of the negative
control was subtracted from the image to correct the background. Calreticulin staining in the anterior
horn of lumbar spinal cord sections was assessed in two control and two SMA mice (P8), and in two
WT and two ALS mice (20 weeks). A minimum of four sections from each mouse was used in the
analysis. Fields of view were selected from each section, and measurements of three distinct regions
that contained alpha motor neurons were taken from each field of view using a rectangular selection
tool of fixed size. A minimum of 45 measurements was made from each experimental group. Statistical
analysis was performed in SPSS version 24 (IBM, New York, NY, USA). The Shapiro-Wilk test was
used to assess the distribution of quantitative data, followed by a Mann-Whitney U test to determine
whether there was a statistically significant difference in calreticulin staining between control and SMA
mice, and between WT and ALS mice.
2.8. Quantitative PCR
Spinal cords were harvested from P7 SMA mice and healthy littermates as well as from
20-week-old SOD1G93A males and age/gender matched WT littermates. RNA was extracted with
the RNeasy MiniKit (Qiagen, Manchester, UK). Reverse transcription was performed using the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Loughborough, UK) for spinal
cords from SMA and control mice. For ALS and WT mice, reverse transcription was performed
using the qPCRBIO cDNA Synthesis Kit (PCR Biosystems, London, UK). qPCRs were performed
using qPCRBIO SyGreen Blue Mix Hi-ROX (PCR Biosystems, London, UK). Primers were as follows:
PolJ F: ACCACACTCTGGGGAACATC; PolJ R: CTCGCTGATGAGGTCTGTGA; Calreticulin F:
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AAGACTGGGATGAACGAGCCAAGA; Calreticulin R: AATTTGACGTGGTTTCCACTCGCC. RNA
polymerase II polypeptide J (PolJ), was used as a validated housekeeping gene as it has previously
been demonstrated as being stably expressed between tissues and in different pharmacological
conditions [29]. Relative gene expression was quantified using the Pfaffl method [30] and primer
efficiencies were calculated with the LinReg PCR software version 2012.0. Statistical analysis was
performed in SPSS version 24 (IBM, New York, NY, USA). The Shapiro–Wilk test was used to test
normality, followed by independent two-tail t-tests to determine whether there was a statistically
significant difference between groups.
3. Results
3.1. Overview of ALS Proteomic Studies
A total of 33 proteomic studies of ALS were eligible for comparison (Table S1) [20,31–62].
As expected, the number of differentially expressed proteins identified in studies correlated with the
sensitivity of the method used, with label-free technologies having identified by far the greatest number
of protein changes compared to 2D-gel approaches. Both in vivo and in vitro models of ALS were used
in analyses, and samples from animal models and ALS patients were equally represented across studies
(Table S1). Samples were derived from a range of sources, including ALS patient cerebrospinal fluid
(CSF) [20,31–40], patient serum [41], a range of cell models [42,44,57,59], ALS patient muscle [45,46],
ALS patient blood mononuclear cells (PBMC) [48], ALS patient spinal cord [61], ALS patient prefrontal
cortex [62], and tissues/cells from various mouse and rat models of ALS including astrocytes [47],
skeletal muscle [53], ventral roots [50], embryonic motor neurons [51], spinal cord [43,49,52,54–56,58],
and hippocampus [60].
3.2. Multi-Study Proteomic Identification of Conserved Molecular Response in ALS Patients and ALS
Experimental Models
Protein expression changes in biofluids may not necessarily correlate with protein changes at
the cellular level and may in fact be contradictory. It is possible that secretion or leakage of proteins
into the CSF or serum may, for example, be accompanied by a concomitant decrease of expression
levels in tissues [63]. Thus, studies that utilized cells/tissues were compared separately to those that
examined biofluids. Comparison across the 12 proteomic studies that examined biofluids from ALS
patients [20,31–41] identified 11 proteins that were consistently changed in the same direction across at
least two studies (Table S2). Of these, one protein—cystatin C—was decreased in expression across four
separate studies [35,37–39] and one protein—chitinase 3-like protein 1—was increased in expression
across three separate studies [32,34,41]. The remaining eight proteins showed opposing directions
of differential expression (Table S3). Gene ontology (GO) analysis was performed using the DAVID
software [18,19] to investigate the likely function of the 11 proteins that showed a consistent change in
expression. “Establishment of localization” was the most enriched biological process term, with seven
of the eleven proteins mapping to it (Figure S1A), and complementary to this, 9 of the 11 proteins were
associated with the term “vesicles”; eight of which were connected to the term “extracellular vesicles”
(Figure S1B). STRING 10 analysis identified association network between four proteins: HBA1, HP, TF
and ORM1 (Figure S1D), all of which appear to be plasma-derived proteins.
Comparison of the 21 studies that investigated proteome changes in tissues and cells from ALS
patients and animal models identified 80 proteins that were differentially expressed across two or
more studies. Of these, 42 proteins showed a consistent direction of differential expression (Table S4),
eleven of which were upregulated across three or more studies: aldolase A [47–49,53,57], superoxide
dismutase 1 [53,54,56] and 2 [44,48,52,58], 14-3-3 protein gamma [44,52,54], calreticulin [44,48,50],
glyceraldehyde-3-phosphate dehydrogenase [49,53,54], heatshock protein 1 [44,54,56], heatshock
protein family A member 8 [44,48,54], peroxiredoxin 2 [44,48,51] and 6 [48,49,56] and glial fibrillary
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acidic protein [47,54,62]. The remaining 38 proteins showed a contradictory direction of expression in
different studies (Table S5).
STRING 10 analysis of the 42 proteins that showed a consistent change in expression revealed
strong association between mitochondrial and endoplasmic reticulum proteins that are involved in
the control of energy homeostasis, oxidative stress response and protein homeostasis (Figure 1A and
Table S6). Within the networks, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was found
to have the greatest number of known associations, linking with proteins involved in each of the
three main domains. GO analysis of the 42 proteins using the DAVID platform supported these
findings and highlighted enrichment of additional terms including programmed cell death, muscle
tissue development and synaptic signaling (Figure 1B and Table S6). Cellular component GO analysis
returned a range of terms, but similar to the bioinformatics finding from the CSF studies, the greatest
number (i.e., 64%) of annotated proteins were associated with the term “extracellular vesicles”
(Figure 1C). Enriched terms in the domain “molecular function” were predominantly associated
with binding activity (Figure 1D).
3.3. Multi-Study Proteomic Identification of Conserved Molecular Perturbations in both SMA and ALS
To identify conserved protein changes common to SMA and ALS, differentially expressed
proteins identified in the ALS multi-study comparison (Tables S2–S5) were compared with the
differentially expressed proteins identified in our previous multi-study comparison of SMA
proteomic datasets [16]. The following 15 proteins were found to be differentially expressed in
both diseases and are summarised in Figure 2: calreticulin [21,44,48,50,64], superoxide dismutase
1 [53,54,56,65–67], aldolase fructose-bisphosphate A [22,47–49,53,57,65,66], heat shock protein family
D, member 1 [22,44,58,65,66], peroxiredoxin 2 [44,48,51,66,67], voltage dependent anion channel
1 [47,52,57,64,66], vimentin [21,44,47,54,64], phosphoglycerate kinase 1 [22,48,49,60,66], annexin
A5 [52,54,66,68], heat shock protein 90 beta family member 1 [47,54,64,66], glyceraldehyde-3-phosphate
dehydrogenase [49,53,54,65–67], heat shock protein HSP 90 alpha [22,44,54,64,65], ATP synthase
subunit alpha mitochondrial [22,47,54,57,60,66], 14-3-3 protein gamma [22,44,52,54,66,68], 2,3-cyclic
nucleotide 3-phosphodiesterase [44,52,64].
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component and (D) molecular function. The top 10 terms from each domain were presented as bars.
White numbers inside the bars indicated the number of annotated proteins. The full list of terms
together with annotated proteins is available in Table S6.
Brain Sci. 2018, 8, 212 9 of 22
Brain Sci. 2018, 8, x FOR PEER REVIEW  9 of 22 
 
Figure 2. Proteins differentially expressed in both spinal muscular atrophy (SMA) and ALS 
proteomic studies. (A) Venn diagram showing the number of proteins differentially expressed in 
SMA proteomic studies compared to ALS proteomic studies. Fifteen of those proteins were identified 
in both SMA and ALS comparison. (B) Heat map of proteins that were differentially expressed in 
both SMA and ALS proteomic studies. Protein names are presented as official gene symbols. The 
reference for each study is given in the corresponding squares of the heat map. Experimental model 
and sample type used in each study are indicated above the table. ALDOA—Aldolase, 
Fructose-Bisphosphate A; ANXA5—Annexin A5; ATP5A1—ATP Synthase Subunit Alpha 
Mitochondrial; CALR—Calreticulin; CNP—2,3-Cyclic Nucleotide 3-Phosphodiesterase; 
GAPDH—Glyceraldehyde-3-Phosphate Dehydrogenase; HSP90AA1—Heat Shock Protein HSP 90 
Alpha; HSP90B1—Heat Shock Protein 90 Beta Family Member 1; HSPD1—Heat Shock Protein 
Family D, Member 1; PGK1—Phosphoglycerate Kinase 1; PRDX2—Peroxiredoxin 2; 
SOD1—Superoxide Dismutase 1; VDAC1—Voltage Dependent Anion Channel 1; VIM—Vimentin; 
YWHAG—14-3-3 Protein Gamma. 
Programmed cell death was one of the most enriched biological process GO terms (Figure 3A) 
and is likely describing the downstream consequences of disease pathogenesis. Other highly 
Figure 2. Proteins differentially expressed in both spinal uscular atrophy (S ) and LS
proteo ic studies. (A) Venn diagram showing the number of proteins differentially expressed
in SMA proteomic studies compared to ALS proteomic studies. Fifteen of those proteins were
identified in both SMA and ALS comparison. (B) Heat map of proteins that were differentially
expressed in both SMA and ALS proteomic studi . Prot in names are prese ted as official
g ne symb ls. The reference for each study is given in the corr sponding squares of the heat
map. Ex erimental model and sample type use in ach study are indicated above the tabl .
ALDOA—Aldolase, Fructose-Bisphosphate A; ANXA5—Annexin A5; ATP5A1—ATP Synthase
Subunit Alph Mitochondrial; CALR—Calreticulin; CNP—2,3-Cyclic Nucleotide
l t 90
lpha; HSP90B1—Heat Shock Protein 90 Beta Family Member 1; HSPD1—Heat Shock Protein Family
D, Member 1; PGK1—Phosphoglycerate Kinase 1; PRDX2—Peroxiredoxin 2; SOD1—Superoxide
Dismutase 1; VDAC1—Voltage Dependent Anion Channel 1; VIM—Vimentin; YWHAG—14-3-3
Protein amma.
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Programmed cell death was one of the most enriched biological process GO terms (Figure 3A) and
is likely describing the downstream consequences of disease pathogenesis. Other highly enriched terms
included regulation of immune system, regulation of protein metabolism, cytoskeleton organization,
and the metabolism of reactive oxygen species. Strikingly, all 15 proteins identified in the comparison
were associated with the cellular component term “extracellular vesicles” (Figure 3B). Transport and
establishment of localization were also among enriched biological process GO terms (Figure 3A).
Enriched terms in the domain “molecular function” were associated with binding activity (Figure 3C).
STRING 10 analyses revealed a strong association network between 14 of the 15 proteins (Figure 3D).
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Figure 3. Bioinformatics analysis of the 15 proteins differentially expressed in both SMA and ALS
proteomic studies. Gene ontology analysis revealed enriched terms connected to (A) biological process,
(B) cellular component, and (C) molecular function. In the biological process domain, only terms with
five or more annotated proteins are presented. Terms are presented as bars, with the white numbers
inside the bars indic ti g number of annotated proteins. The full list of terms together ith annotated
proteins is available in Table S7. (D) STRING 10 association network of protei s that wer differentially
expressed in SMA and ALS. Proteins connected to metabolic function, oxidative stress response and
protein stability were identified in the network from Figure 3A. The type of the association between
proteins is indicated by the color (pink: experimentally determined interactors; light blue: interactors
form curated databases; grey: protein homology; black: co-expression; yellow: text-mining; dark blue:
gene co-occurrence; green: gene neighborhood).
Reac ome pathway analysis [24] was p form d to further explore which pathways 15 proteins
dysregulated in both ALS and SMA are associated with. At the genome-wide view, pathways that
were over-represented were largely complementary to those identified by the GO analysis, above
(Figure 4A). Of the over-represented pathways identified, only two—“metabolism of proteins” and
“vesicle-mediated transport”—were shown to have a direct connection to each other (Figure 4B) [69].
The molecular highway connecting these two pathways is the “endoplasmic reticulum (ER) to Golgi
anterograde transport” pathway [69], suggesting this as a core pathway upon which ALS and SMA
disease mechanisms converge. Of particular note is that calreticulin (CALR) was associated with both
“metabolism of proteins” and “vesicle-mediated transport” pathways (Figure 4B) and was the only
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protein identified with a consistent direction of differential expression across SMA and ALS proteomic
studies (Figure 2B).
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Figure 4. Reactome analysis of the 15 proteins differentially expressed in both SMA and ALS proteomic
studies. (A) Genome-wide overview of Reactome pathway analysis identified several over-represented
pathways (highlighted using a colored scale on the right-hand side that indicates false discovery rate
(FDR)), including endoplasmic reticulum (ER) to Golgi anterograde transport [69], (B) Zoomed view of
“metabolism of proteins” nd “vesicle-mediated ransport” pathways. Over-represented pathways are
indicated by the red line. Proteins annotated to each pathway are shown.
3.4. Calreticulin Expression i Dy regulated in Spinal Cor sue from ALS and SMA Mice
None of the five proteomic studies that analyzed whole spinal cord extracts from mouse or
rat models of ALS reported detection of calreticulin [49,52,54–56] (Table S1) (but this is perhaps not
surprising since each of these studies utilized a 2D-gel electrophoresis protocol which identifies
significantly fewer proteins compared to more recent techniques such as iTRAQ or label-free
quantification). Though induced pluripotent st m cell (iPSC)-derived motor neurons have been
studied in the context of SMA [64], there have been no proteomic studies of spinal cord or primary
motor neurons isolated from animal models of SMA to date. We therefore performed quantitative
western blot analysis of spinal cord extracts from mouse models of ALS (SOD1G93A) and SMA (severe
‘Taiwanese’ model) at late symptomatic time-points to determine the expression levels of calreticulin
relative to healthy littermate controls. In spinal cord extracts from ALS mice, calreticulin expression
was significantly increased by an average of 43% (p = 0.003) (Figure 5A). In contrast, however,
calreticulin expression in SMA spinal cord extracts was significantly reduced by 22% compared
to that of controls (p = 0.008) (Figure 5B). Immunohistochemistry analysis of the ventral horn of lumbar
spinal cord sections from control and age-matched (P8) SMA mice closely aligned with the quantitative
western blotting, showing calreticulin was reduced by an average of 26% in SMA compared to
controls (p < 0.001) (Figure 5C). A significant difference in calreticulin expression was not detected by
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immunohistochemistry analysis of ALS and WT lumbar spinal cord sections (Figure 5C), but RT-PCR
analysis of calreticulin gene expression aligned with the trends seen by western blot results, showing a
statistically significant increase in ALS vs. WT (Figure 5D) and a slight, but statistically significant,
decrease in SMA vs. control spinal cords (Figure 5E).
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Figure 5. Dysregulated expression of calreticulin in spinal cord extracts from late-sy ptomatic ALS
mice (20 week) and late-symptomatic SMA mice (P8). Representative western blots showing (A) a 43%
increase in calreticulin (CALR) expression levels in spinal cords of ALS mice (n = 4) compared to wild
type (WT) mice (n = 5); (B) a 26% reduction of calreticulin expression in SMA mice (n = 5) compared to
control mice (n = 5). Gr phs are presented as i tegrated density of easured protein norm lized to
total protein (Coomassie stained gel). Densitometry measurements for individual samples d mean
of the group are shown, with error bars showing standard error from the mean; (C) Representative
immunohistochemistry images showing calreticulin expression in the ventral horn of lumbar spinal
cord sections in 20-week-old WT and ALS mice and in control and age-matched (P8) SMA mice. Scale
bar = 50 µm. Densitometry measurements of calreticulin levels in alpha motor neurons are presented
as mean optical density, with error bars showing standard error from the mean. (D) Calreticulin gene
expression levels in WT and ALS mice, and; (E) in control and SMA mice, as determined by RT-PCR.
Expression levels of calreticulin were normalized to PolJ. Error bars represent standard error from the
mean. CALR—Calreticulin; CTR—Control; WT—Wild Type. ns—Not Significant; * p < 0.05; ** p < 0.01;
*** p < 0.001.
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4. Discussion
Here, we used a comparative approach to identify core molecular perturbations shared between
SMA and ALS with the aim of understanding common molecular mechanisms of disease pathogenesis.
Multi-study comparisons of published proteomic datasets identified 15 proteins that were dysregulated
across two of more separate studies in both SMA and ALS. These proteins therefore represent
a potential “molecular fingerprint” of disease pathogenesis that is shared between both diseases.
Bioinformatics analysis of the 15 differentially expressed proteins identified over-representation of
several pathways including cell death, protein metabolism and vesicle-mediated transport pathways;
with the latter two being linked via the ER to Golgi anterograde transport pathway. One of the
15 proteins, calreticulin, was strongly associated with this pathway because of its involvement with
both protein metabolism and vesicle-mediated transport pathways [69,70]. Using quantitative western
blot and immunohistochemistry, we demonstrated for the first time that calreticulin is reduced in
expression in spinal cords from late-symptomatic SMA mice, and in agreement with proteomic studies
of other ALS cells and tissue [44,48,50], we measured increased levels of calreticulin in spinal cord
extracts from symptomatic ALS SOD1G93A mice.
Golgi fragmentation and ER stress were both identified as key pathological features in sALS [71]
and transgenic mouse models of fALS [72], and both were evident at a pre-symptomatic stage of disease,
directly implicating them in disease pathogenesis [72,73]. It was only recently, however, by studying
induced pluripotent derived-motor neurons from SMA patients, that ER stress was implicated in SMA
pathogenesis [74]. In line with this, ER stress was also found to be a prominent feature of spinal motor
neurons from a mouse model of X-linked spinal and bulbar muscular atrophy [75], and alterations of
Golgi apparatus were previously reported in anterior horn cells from patients with X-linked spinal
and bulbar muscular atrophy [76] and in fibroblasts from patients with a rare autosomal dominant
form of SMA [77].
ER stress and Golgi alterations can both be triggered by impaired ER-Golgi transport mechanisms,
ultimately leading to induction of the cell death-related pathways [78,79]. Dysregulated protein
transport between ER and Golgi, identified in the bioinformatics analysis here, therefore highlights the
possibility that the same biological mechanism is responsible for aspects of disease pathogenesis in
SMA and ALS. Indeed, ALS-associated mutant SOD1, TDP-43 and FUS proteins have been reported to
inhibit ER-Golgi trafficking in neuronal cells [78,80]. Importantly, dysregulation of ER-Golgi trafficking
preceded protein aggregation, ER stress, Golgi fragmentation and axon degeneration in NSC-34 cells
expressing mutant SOD1 [78], and dysregulated ER-Golgi trafficking was observed as an early event in
embryonic cortical and motor neurons in a mouse model of ALS [80]. Over-expression of Rab1, a master
regulator of ER-Golgi transport, restored ER-Golgi trafficking and prevented induction of ER stress,
formation of intracellular aggregations and apoptosis in in vitro model of ALS [80]. Several studies
also indicate a role for defective ER-Golgi transport in SMA. SMN interacts with α-COP, a member
of COPI vesicles that mediates ER-Golgi transport [81–84], and knockdown of α-COP caused SMN
accumulation in Golgi apparatus of neuron-like NSC34 cells [82] and produced developmental defects
in motor neuron-like NSC34 cells and primary cortical murine neurons [84]. Over-expression of human
α-COP reversed motor neuron defects in SMN-depleted NSC34 cells [83,84] and in motor neurons
from a zebrafish model of SMA [84]. A role for defective ER to Golgi transport in ALS and SMA
pathogenesis is further supported by our finding here that all 15 of the differentially expressed proteins,
common to SMA and ALS, mapped to “extracellular vesicles” in cellular compartment GO analysis.
Calreticulin is a multifunctional protein involved in a range of processes, including the regulation
of Ca2+ homeostasis in the ER, chaperone activity in secretory pathways, folding of nascent proteins,
regulation of immune system, and modulation of cell adhesion [17]. Its chaperone activity in the ER
is dependent on calcium (Ca2+) levels and perturbations in Ca2+ homeostasis can disrupt the correct
functioning of protein folding machinery [85]. It has been suggested that defective Ca2+ handling
is responsible for triggering calreticulin depletion in ALS vulnerable motor neurons, leading to ER
stress and apoptosis [86]. In addition, defects in Ca2+ handling have been demonstrated in both
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SMA [87–89] and ALS [90–92]. Alterations in calcium homeostasis are also known to inhibit ER-Golgi
trafficking [93], indicating a possible common mechanism that drives ER and Golgi defects in SMA
and ALS. Calreticulin was previously identified from proteomic studies as having increased levels in
iPSC-derived motor neurons from type I SMA patients [64] and in SMA mouse muscle [21], and this
was verified biochemically in muscles from SMA mice and SMA patients [21]. In contrast, we observed
a statistically significant decrease of calreticulin levels in spinal cord extracts from late symptomatic
mice. In proteomic studies of ALS, calreticulin was found to be increased in the ventral roots from
the spinal cord of ALS SOD1G93A mice [50], blood mononuclear cells from ALS patients [48], and in
TDP-43 knockdown SH-SY5Y cells [44], and in agreement with this, we also found increased levels
of calreticulin in spinal cord extracts from late-symptomatic ALS SOD1G93A mice. This is, however,
in contrast with a biochemical study of lower motor neurons isolated from ALS SOD1G93A mice that
reported decreased expression of calreticulin [86].
When taken together, there is certainly evidence to support a role for calreticulin dysregulation
in both ALS and SMA, but it is important too, to consider possible explanations for the opposing
patterns of calreticulin expression reported in different studies, as this may offer further insights
into disease mechanisms. In the case of whole spinal cord from ALS mice, for example, differences
in calreticulin expression in different cell populations could, according to a theory proposed by
Bernard-Marissal et al. [86], have contributed to the overall calreticulin expression levels, masking
changes that were previously reported to be specific to vulnerable lower motor neurons [86]. This could
also offer an explanation for why western blotting and RT-PCR analysis of whole spinal cord
extracts revealed a statistically significant increase in calreticulin protein and gene expression in
ALS, but immunohistochemistry analysis of lumbar spinal cord sections did not. It has been shown
that calreticulin levels increase under stress conditions prior to being secreted to the cell surface;
a process that is associated with the functional role of calreticulin in apoptosis [94]. It is thus possible
that opposing directions of perturbed calreticulin expression reflect ongoing cycles of apoptosis in
vulnerable motor neurons. The time-course of disease is another potential variable to consider, since
Bernard-Marissal et al. [86] studied ALS mice up to 110 days of age, compared to the later time-point
of 140 days in the present study. The obvious limitations of using a late-symptomatic animal model
are that it cannot determine whether changes in protein expression levels are causative of disease
pathology or are simply reflective of cell death processes. It would be of interest, therefore, to verify the
expression of calreticulin throughout different stages of disease development in both SMA and ALS
and determine whether other cell populations in proximity of vulnerable motor neurons or unaffected
spinal cord regions contribute to alterations in calreticulin levels. Further work is clearly warranted too,
to examine the relationship between calreticulin perturbations, defective Ca2+ handling, and ER and
Golgi defects in SMA and ALS, and whether targeting these pathways offers a potential therapeutic
approach to both diseases.
In this study we demonstrated that calreticulin expression is altered at both the transcript
and protein level in ALS and SMA, so we were interested to determine the extent to which the
other proteomic changes common to ALS and SMA can be traced back to aberrant gene regulation.
None of the SMA and ALS proteomic studies used in this comparison also investigated changes using
transcriptomics approaches, but a small number of transcriptomic studies of SMA and ALS have
been conducted separately using comparable experimental models. For ALS, two transcriptomic
studies investigated gene alterations in patient blood mononuclear cells [95,96], but none of the four
proteins found to be differentially expressed in the proteomic study (Table S2) were reported to be
differentially expressed at the gene level in either of the two studies. One of the eight proteins that were
differentially expressed in spinal cords from ALS SOD1G93A mice [54] (Figure 2), ATP5A1, was also
found to be differentially expressed at the gene level in a separate study [97]; with both proteomic and
transcriptomic studies having reported an increased expression in ALS. For SMA, two proteins were
differentially expressed in mouse embryonic stem cell (ESC)-derived motor neurons (Figure 2) [68],
and one of these—ANXA5—was also found to be differentially expressed in a separate transcriptomic
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study [98], but with the opposite direction of change. None of the five proteins differentially expressed
in iPSC-derived motor neurons from Type I SMA patients (Figure 2) [64] were found to be differentially
expressed in a transcriptomic study of similar cell lines [74]. The altered expression of calreticulin
(verified in this study at both transcript and protein level), and the altered expression of ATP5A1
at the protein level (Figure 2) [22,47,54,57,60,66] and at the transcript level [97], suggest that these
molecular changes could be due to aberrant gene transcription. The majority of well-characterized
molecular changes in SMA and in many fALS cases, however, have been traditionally attributed
to dysregulation of RNA metabolism [14], and the apparent lack of overlap between the profile of
differentially expressed proteins summarised in this study with differentially expressed genes found in
separate studies supports the possibility that at least some changes may be due to post-transcriptional
gene regulation defects. Perturbed post-transcriptional gene regulation in both diseases has been
associated with several defective RNA processing pathways, including those that regulate RNA
splicing [99], RNA stability and translation [100,101]. A growing body of evidence also suggests
physical and functional links between SMA and ALS-associated proteins, including SMN, FUS, TDP43
and SOD1, some of which are RNA-binding proteins (summarized in recent reviews [14,15]). This may
also offer an explanation of how perturbations in RNA processing pathways extend to fALS cases with
mutations in non-RNA binding proteins such as SOD1 [14]. Taken together, it seems that aberrant
post-transcriptional gene regulation might contribute to some, but perhaps not all, of the molecular
defects in SMA and ALS. Further work is clearly warranted though to establish the precise relationship
between ALS and SMA transcriptional and post-transcriptional changes and protein expression
changes. When doing so, it will be important to consider these relationships in the same cell/tissue
type, matched for both relative age and disease timeline.
The aim of this study was to identify the molecular overlap between SMA and ALS, but it is
important not to overlook the results from the comparative analysis of ALS proteomic data sets
(Tables S2–S5) as these are likely to provide a useful resource for research aimed at understanding
ALS-specific pathways and biomarkers. Whilst several of these proteins have gained significant
attention in the context of ALS, including the putative auxiliary biomarker, cystatin C [102] and
SOD1 [15], several proteins appear to have been overlooked when these data sets were considered
in isolation. One such protein, aldolase A, for example, was increased in expression in five separate
studies of ALS cells and tissues [47–49,53,57]. Given its importance in glycolysis [103], overexpression
of this protein is highly likely to reflect perturbed metabolic activity. Indeed, mitochondrial
dysfunction [104] and ER stress [105] are known early pathological features and a major contributing
factor of motor neuron death in ALS. Not surprisingly, most of the dysregulated proteins identified in
tissues and cells from ALS patients and models were associated with energy homeostasis, oxidative
stress response and control of protein stability, confirming the importance of ER and mitochondria
in ALS disease pathways. Recently, defective ER-mitochondria crosstalk has received attention
in the context of ALS pathogenesis, implying that ER and mitochondria perturbations cannot be
perceived separately, but rather as a complex network of changes that together contribute to ALS
pathogenesis [106,107]. This therefore presents an opportunity for the development of therapeutic
approaches for ALS to simultaneously target functional defects in the ER and mitochondria [106,107].
Another important finding is that most proteins with a consistent direction of differential
expression across ALS proteomic studies were associated with extracellular vesicles. Significant
attention has been given to extracellular vesicles in the context of neurodegenerative disorders,
including ALS, as a potential source of biomarkers and as a possible mechanism of misfolded
protein spreading in CNS [108]. Mutant SOD1 and TDP-43 proteins are among molecules whose
prion-like properties, facilitated by exosome transport, are thought to contribute to spreading of
protein misfolding in ALS [108]. Interestingly, all 15 proteins identified in both ALS and SMA were
also associated with extracellular vesicles. A recent study reported increased levels of exosomes in
culture media from SMN-depleted cells, SMA patient fibroblasts, and in serum from SMA patients
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and mouse model of SMA [109], indicating alterations in exosome transport as another shared link
between SMA and ALS.
To conclude, we provide evidence that integrating multi-study comparisons of proteomic datasets
with bioinformatics analysis can help to unravel complex disease mechanisms. The 15 proteins
identified here represent the core molecular overlap between SMA and ALS; many of which, have not
until now, been considered in isolation. The identification of over-represented pathways, including
two that converge on ER-Golgi trafficking, offers further insights into mechanistic cross-talk between
SMA and ALS. Together, these findings offer significant insights into potential common targets that
may help to guide the development of new therapies for both diseases.
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Table S1: ALS proteomic studies used in the comparison, Table S2. Proteins differentially expressed in the same
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that showed consistent direction of differential expression in ALS cells and tissues across two or more proteomic
studies, Table S5. Proteins that showed contradictory direction of differential expression in cells and tissues across
two or more proteomic studies of ALS, Table S6. GO term analysis of proteins that were differentially expressed
in tissues and cells in ALS proteomic studies, Table S7. GO term analysis of proteins that were differentially
expressed in SMA and ALS proteomic studies.
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